6 completed, 5 recruiting, 2 active not recruiting, 2 terminated. 6 Phase 2, 4 Phase 1, 3 Not applicable, 2 Phase 3, 1 Phase 4.
Follow Histamine H2 Antagonists: new trials by email Literature Review of Histamine H2 Antagonists trials Research Report on Histamine H2 Antagonists
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010) MK-2010, Sacituzumab tirumotecan, Histamine H1 Receptor Antagonist - Advanced Solid Tumors, Malignant Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 200 | 2026-10-07 | 2026-10-15 |
| Real-world Evaluation of the Effectiveness of Immunoglobulin-Histamine Complex, IHC (Histoglob) in Chronic Urticaria Antihistaminics, H2 blockers, Leukotriene antagonists, Immunoglobulin/Histamine Complex (IHC) Injection - Chronic Urticaria | Completed | Bharat Serums and Vaccines Limited | 660 | 2025-12-31 | 2026-10-02 | |
| Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat Nirogacestat, Nirogacestat and Famotidine, Nirogacestat and Rabeprazole - Healthy | Phase 1 | Completed | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 24 | 2025-08-21 | 2026-05-08 |
| A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 770 | 2025-04-09 | 2026-10-13 |
| Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine - Lung Neoplasm Malignant | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 60 | 2025-03-20 | 2026-10-13 |
| A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors OKN4395, Pembrolizumab, Fasting - Solid Tumours, Sarcoma | Phase 1 | Recruiting | Epkin | 146 | 2025-01-23 | 2026-06-11 |
| Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) Sacituzumab tirumotecan, Pemetrexed, Carboplatin - Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 550 | 2024-06-11 | 2026-09-11 |
| Famotidine and Antacids for Treatment of Dyspepsia Intravenous Famotidine, Oral Maalox/ Mylanta - Dyspepsia, GERD | Phase 4 | Recruiting | Stony Brook University | 80 | 2023-11-09 | 2026-06-02 |
| A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) Paclitaxel, Irinotecan, Pembrolizumab - Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 230 | 2023-05-16 | 2026-10-07 |
| Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III) UX053, Placebo, Antipyretic - Glycogen Storage Disease Type III | Phase 1 / Phase 2 | Terminated | Ultragenyx Pharmaceutical Inc | 9 | 2021-10-18 | 2024-04-16 |
| Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) elotuzumab, placebo for elotuzumab, methylprednisolone - IgG4 Related Disease, IgG4-RD | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 8 | 2021-10-13 | 2026-02-05 |
| Prevention of Broncho-aspiration (BA) in Adult Subjects During Their ICU Stay Bed Head elevation, H2 blockers and mouth wash, Data collection for comparison - Bronchial Aspiration | Not applicable | Completed | Marshall University | 159 | 2021-08-03 | 2023-04-04 |
| Dietary Supplement With and Without a Probiotic Complex oligosaccharide, Probiotic, PPI - Healthy Adult Subjects | Not applicable | Completed | Prolacta Bioscience | 62 | 2020-03-13 | 2025-03-18 |
| Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs) Cabazitaxel, Antihistamine, Corticosteroid - Circulating Tumor Cell, Metastatic Prostate Cancer | Phase 2 | Unknown | Erasmus Medical Center | 140 | 2017-02-21 | 2021-08-20 |
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer histamine-2 receptor antagonist, Placebo - Peptic Ulcer | Not applicable | Completed | Kaohsiung Veterans General Hospital. | 228 | 2012-01-01 | 2019-03-11 |
| Proton Pump Inhibitors and Risk of Community-acquired Pneumonia esomeprazole, omeprazole, pantoprazole - Gastroesophageal Reflux Disease (GERD), Community-acquired Pneumonia | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 4238504 | 2011-09-01 | 2015-09-22 |
Carcinoma, Non-Small-Cell Lung (2) · Gastroesophageal Reflux (2) · Parkinson Disease 4, Autosomal Dominant Lewy Body (2) · Bulbo-Spinal Atrophy, X-Linked (1) · Chronic Urticaria (1) · Colorectal Neoplasms (1) · Community-Acquired Pneumonia (1) · Dermatofibrosarcoma (1) · Dyspepsia (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Fallopian Tube Neoplasms (1) · Glycogen Storage Disease Type III (1) · Histiocytoma, Malignant Fibrous (1) · Immunoglobulin G4-Related Disease (1)
Merck Sharp & Dohme LLC (5) · Bharat Serums and Vaccines Limited (1) · Canadian Network for Observational Drug Effect Studies, CNODES (1) · Epkin (1) · Erasmus Medical Center (1) · Kaohsiung Veterans General Hospital. (1) · Marshall University (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Prolacta Bioscience (1) · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (1) · Stony Brook University (1) · Ultragenyx Pharmaceutical Inc (1)
United States (12) · Italy (5) · Spain (4) · Taiwan (4) · Canada (3) · Chile (3) · Japan (3) · Poland (3) · South Korea (3) · Thailand (3) · Turkey (Türkiye) (3) · Argentina (2) · Australia (2) · Brazil (2) · China (2)
Dr Saswata Banerjee (1) · John H. Stone, MD, MPH (1) · Juan Sanabria, MD MSc FACS (1) · Kristian Filion, PhD (1) · Mary Beth Brune, MD (1) · Ping-I Hsu, Bachelor (1)
2023 (4), UM1AI144298 (1)